#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Experts Issue GLP-1 Guidance for NET Care
A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
Ozempic in Pro-Eating-Disorder Communities
A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.
Semaglutide and aspiration risk in surgery
New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
How chemists test what's in GLP-1 drugs
A new peer-reviewed method identifies nine GLP-1 drugs at once. Here is why that kind of identity testing matters right now.
Retatrutide and gallbladder disease risk
Retatrutide is an investigational GLP-1, GIP and glucagon triple agonist. Here is what the trial and label data show about gallbladder risk.
How GLP-1 weight loss drugs really differ
Novo's CEO says patients want optionality. Here is what the approved labels and the single head-to-head trial say really separates these drugs.
GLP-1 gastroparesis symptoms and the gaps
A 2026 systematic review found only 12 published case reports of GLP-1 gastroparesis. Here is what they showed, and what they cannot tell you.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.